US Implements New Tariffs on Imported Drugs, Furniture, Trucks

The United States has announced additional tariffs targeting a range of imported goods, including pharmaceuticals, furniture, and trucks. This move signals an escalation in trade measures that could impact various sectors of the economy and international commerce.

US Tariffs Shake Global Trade Landscape

With the specter of sweeping new US import duties looming over global markets, industries across continents are bracing for a turbulent autumn. The recent announcement by Donald Trump of significant tariff hikes on selected foreign goods—most notably patented pharmaceuticals, foreign-made trucks, and imported furniture—has already begun to send shockwaves through financial markets and boardrooms alike.

Targeting Medicine: Exemptions and European Unease

The latest measures take aim specifically at “branded or patented” medicines, with generic drugs left largely unaffected—a distinction that limits overall market impact but does little to calm industry nerves. According to economist Neil Shearing of Capital Economics, generics represent just 10% of the American pharmaceutical spend by value. Nonetheless, the move has set off alarm bells within the European pharmaceutical sector. The European Federation of Pharmaceutical Industries and Associations (Efpia) warns that these tariffs could trigger the “worst-case scenario”—driving up costs, disrupting supply chains, and threatening access to crucial treatments.

A recent agreement shields the European Union from some fallout by capping new tariffs on its drug exports at 15%. However, this arrangement feels precarious amid persistent legal uncertainties and growing unease in key exporting countries such as Germany. In contrast, British officials emphasize their ongoing “active dialogue” with Washington. Meanwhile, anxiety is mounting in Asia; as highlighted by Louise Loo from Oxford Economics, countries like Singapore—renowned for high-value pharmaceutical production—stand particularly exposed.

Tough Choices for Pharma Giants Under Pressure

Multinational drugmakers are now recalibrating strategies. Facing the threat of up to a 100% tariff—and even whispers of a possible 200% penalty for slow compliance—industry leaders are moving swiftly to invest in US-based production facilities. Companies such as Switzerland’s Novartis, armed with a $23 billion investment plan, are pledging rapid site launches. Others—including German and British firms like Bayer and GSK—take a more cautious stance: “We are evaluating,” says Bayer, while GSK stresses constructive talks with US authorities.

Several factors explain this response:

• Accelerating construction of domestic manufacturing sites.
• Reinforcing supply chains against regulatory risk.
• Pursuing negotiations for regulatory relief.

Beyond Pharma: Trucks and Furniture Also Hit Hard

Yet it’s not just medicines under fire. A fresh 25% surcharge will soon apply to all heavy-duty trucks built outside US borders—a bid to shield domestic manufacturers such as Kennworth, Mack Trucks, and Peterbilt. The announcement sent shares tumbling at rivals like Sweden’s Volvo and Germany’s Daimler. Citing “multiple reasons, primarily security,” Trump justified this bold step.

Additionally, parts of the furniture market—heavily reliant on Asian imports—face new duties reaching up to 50%. For major US retailers such as Wayfair and Williams Sonoma, this signals an uncertain season ahead.

In short, these sweeping protectionist policies mark a defining moment for international commerce as stakeholders worldwide scramble to adjust before October arrives.